DGX vs LH
Quest Diagnostics Inc (DGX) and Labcorp Holdings Inc. (LH) are both filed with the SEC under Services-Medical Laboratories. The two are within rounding of one another by market cap ($27.0B and $27.3B); LH trades at the higher fiscal-year P/E (32.2× against 28.0×); DGX reports the higher net margin (9.0% against 6.3%); LH grew sales faster over three years (+5.6% against +3.7%); and over the past year DGX returned +37.3% against LH's +22.7%.
| DGX | LH | |
|---|---|---|
| Last close | $242.76 | $335.11 |
| Market cap | $27.0B | $27.3B |
| P/E (FY) | 28.0× | 32.2× |
| P/S | 2.4× | 2.0× |
| EV/EBITDA | 15.2× | 15.7× |
| Gross margin | — | 28.8% |
| Operating margin | 14.1% | 9.9% |
| Net margin | 9.0% | 6.3% |
| Return on equity | 14.2% | 10.5% |
| Sales growth (3y) | +3.7% | +5.6% |
| EPS growth (3y) | +3.2% | -9.2% |
| Dividend yield | 1.3% | 0.9% |
| 1-year return | +37.3% | +22.7% |
Screener snapshot — prices as of 2026-08-28. Each side's last close is the most recent session the snapshot holds for that company, which can be an earlier one, and its 1-year return is measured to that close. Market caps struck on 2026-08-27. Last close, market cap and the 1-year return are price figures; every other row is computed over the company's latest filed fiscal year — FY2025 (ended 2025-12-31) for both. — not published for this company. A ratio goes unpublished for more than one reason: a component the calculation needs is not on file, the filing does not tag the line it is read from, or the calculation is not defined on the filed basis — EV/EBITDA is not printed on non-positive EBITDA, and return on equity is not computed on a zero or negative equity base.
Who holds them, and who has traded them
| DGX | LH | |
|---|---|---|
| Institutional holders (13F) | 1,059 | 1,015 |
| Insider buyers − sellers (180d) | -5 | -4 |
| Congressional trades disclosed (180d) | 2 | 1 |
| Executive-branch officials on file — trades disclosed (180d) | 2 | 2 |
Counts only. The congressional figures count transactions dated in the trailing 180 days and disclosed in STOCK Act periodic transaction reports; amounts are filed as ranges and are never summed. The executive-branch figures count the same window of transactions, and they are scoped to one roster. The officials OGE posts for direct download. Insider buyers − sellers counts distinct people filing open-market Form 4 purchases minus distinct people filing open-market sales over the trailing 180 days, capped at ±5.
DGX vs LH: common questions
- Is DGX bigger than LH?
- LH carries the larger market cap — $27.3B against $27.0B, both struck on 2026-08-27.
- Which trades at a higher P/E, DGX or LH?
- LH, at a fiscal-year 32.2× against 28.0× for DGX. Both are price ÷ latest full-year diluted earnings per share, not a trailing-twelve-month P/E.
- How have DGX and LH performed over the past year?
- DGX returned +37.3% and LH +22.7%, measured on the trailing calendar year to the last close.
- How many institutions hold DGX and LH?
- 1,059 13F filers report a position in DGX and 1,015 in LH, on the latest quarter in the panel.
- Are DGX and LH in the same industry?
- Both are filed with the SEC under Services-Medical Laboratories, which is the classification this pairing is built on.
DGX overview → · LH overview → · DGX institutional ownership → · LH institutional ownership → · Congress and DGX → · Congress and LH → · Executive branch and DGX → · Executive branch and LH →
Stock comparisons lists every pair this site publishes.
Source: SPZCO — https://spzco.com/vs/dgx-vs-lh